These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36270754)

  • 41. User-centred clinical decision support to implement emergency department-initiated buprenorphine for opioid use disorder: protocol for the pragmatic group randomised EMBED trial.
    Melnick ER; Jeffery MM; Dziura JD; Mao JA; Hess EP; Platts-Mills TF; Solad Y; Paek H; Martel S; Patel MD; Bankowski L; Lu C; Brandt C; D'Onofrio G
    BMJ Open; 2019 May; 9(5):e028488. PubMed ID: 31152039
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
    Hassman H; Strafford S; Shinde SN; Heath A; Boyett B; Dobbins RL
    Am J Drug Alcohol Abuse; 2023 Jan; 49(1):43-52. PubMed ID: 36001871
    [No Abstract]   [Full Text] [Related]  

  • 43. Use of long-acting injectable buprenorphine in the correctional setting.
    Martin RA; Berk J; Rich JD; Kang A; Fritsche J; Clarke JG
    J Subst Abuse Treat; 2022 Nov; 142():108851. PubMed ID: 35939914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pregnant and Postpartum Individuals' Knowledge, Attitudes, and Perceptions of Extended-release Buprenorphine for Treatment of Opioid Use Disorder.
    Lai M; Bowman J; Charles J; Smid MC
    J Addict Med; 2023 May-Jun 01; 17(3):342-345. PubMed ID: 37267186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Case series: Voluntary discontinuation of sublingual buprenorphine treatment for opioid use disorder using extended-release buprenorphine.
    Rodriguez CP; Suzuki J
    Am J Addict; 2023 May; 32(3):314-317. PubMed ID: 36941795
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder.
    Kranzler HR; Lynch KG; Crist RC; Hartwell E; Le Moigne A; Laffont CM; Andorn AC
    Int J Neuropsychopharmacol; 2021 Feb; 24(2):89-96. PubMed ID: 32920647
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
    Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
    Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.
    Mooney LJ; Nielsen S; Saxon A; Hillhouse M; Thomas C; Hasson A; Stablein D; McCormack J; Lindblad R; Ling W
    Contemp Clin Trials; 2013 Mar; 34(2):196-204. PubMed ID: 23159524
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hospital-initiated Extended-release Injectable Buprenorphine Using a Novel Reallocation Initiative From an Outpatient Addiction Medicine Clinic.
    Ganetsky VS; Salzman M; Carroll G; Heil J; Sutton J; Visioli VM; Currie S; Schmidt R; Baston KE; Haroz R
    J Addict Med; 2023 Jan-Feb 01; 17(1):108-110. PubMed ID: 36166670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study.
    Strang J; Reed K; Bogdanowicz K; Bell J; van der Waal R; Keen J; Beavan P; Baillie S; Knight A
    Eur Addict Res; 2017; 23(2):61-70. PubMed ID: 28268215
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review.
    Shirk SD; Ameral V; Kraus SW; Houchins J; Kelly M; Pugh K; Reilly E; Desai N
    J Dual Diagn; 2021; 17(3):207-215. PubMed ID: 34176448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Healthcare utilization and costs associated with treatment for opioid dependence.
    Shah A; Duncan M; Atreja N; Tai KS; Gore M
    J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients.
    Ross RK; Nunes EV; Olfson M; Shulman M; Krawczyk N; Stuart EA; Rudolph KE
    medRxiv; 2024 Apr; ():. PubMed ID: 38343815
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
    Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
    Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial.
    McAnulty C; Bastien G; Eugenia Socias M; Bruneau J; Foll BL; Lim R; Brissette S; Ledjiar O; Marsan S; Talbot A; Jutras-Aswad D;
    Drug Alcohol Depend; 2022 Oct; 239():109604. PubMed ID: 36037586
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study.
    Ling W; Nadipelli VR; Aldridge AP; Ronquest NA; Solem CT; Chilcoat H; Albright V; Johnson C; Learned SM; Mehra V; Heidbreder C
    J Addict Med; 2020; 14(5):e233-e240. PubMed ID: 32187112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials.
    Jones AK; Ngaimisi E; Gopalakrishnan M; Young MA; Laffont CM
    Clin Pharmacokinet; 2021 Apr; 60(4):527-540. PubMed ID: 33135125
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables.
    Rudolph KE; Díaz I; Hejazi NS; van der Laan MJ; Luo SX; Shulman M; Campbell A; Rotrosen J; Nunes EV
    Addiction; 2021 Aug; 116(8):2094-2103. PubMed ID: 33340181
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.
    Andraka-Christou B; Capone MJ
    Int J Drug Policy; 2018 Apr; 54():9-17. PubMed ID: 29324253
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Use of Once-monthly Injectable Buprenorphine for the Treatment of Opioid Use Disorder in Postpartum Women: A Case Series.
    Shadowen C; Moeller FG; Martin CE
    J Addict Med; 2021 Jul-Aug 01; 15(4):292-296. PubMed ID: 34397780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.